PAXOBROOK TABLET

Paxobrook Tablet is a prescription antiviral medicine containing Nirmatrelvir 150 mg and Ritonavir 100 mg, used to treat mild to moderate COVID-19 in adults and adolescents at high risk of severe illness. It is a targeted therapy designed to help reduce viral load and prevent disease progression.

Nirmatrelvir works by inhibiting the replication of the SARS-CoV-2 virus, while ritonavir enhances its effectiveness by slowing the metabolism of nirmatrelvir in the body. This combination ensures higher drug levels for optimal antiviral activity, making Paxobrook an effective option for early COVID-19 treatment.

Paxobrook Tablet should be taken strictly under medical supervision, especially in patients with underlying health conditions. It is recommended as part of a comprehensive COVID-19 management plan to reduce the risk of hospitalization and severe complications.

Product Feature

• Combination of Nirmatrelvir and Ritonavir
• Used for the early treatment of COVID-19 infection
• Helps reduce viral replication in the body
• Recommended for high-risk patients
• Oral tablet formulation
• Prescription-only antiviral medication

How It Helps

• Inhibits SARS-CoV-2 virus replication with Nirmatrelvir
• Ritonavir boosts the effectiveness by slowing Nirmatrelvir metabolism
• Reduces risk of severe COVID-19 in adults and adolescents
• Supports early intervention for faster recovery
• Oral formulation allows convenient home administration under supervision